Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Astria Therapeutics, Inc.

< Previous 1 2 3 4 Next >
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Present at Upcoming Global Angioedema Forum
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Present at Upcoming Bradykinin Symposium
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.